ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Outcomes Are Poor in Triple Class–Exposed* RRMM Patients1,2

Although advancements in the treatment of RRMM have transformed outcomes, deep and durable responses remain difficult to achieve after patients have received an IMiD® agent, a PI, and an anti-CD38 antibody.1-3

When patients relapse, their disease becomes increasingly nonresponsive to the 3 main classes of treatments,1,4 resulting in:

  • Shorter remissions between treatments4,5
  • Rising burden of continuous administrations6,7
  • Decreased quality of life6,7
Course of Disease Graphic

No standard of care exists for triple class–exposed* RRMM, and several studies have demonstrated poor outcomes in these patients4

Outcomes after
triple-class exposure*





3-5 months


Novel mechanisms of action are needed in the management of RRMM1

After receiving multiple lines of therapy, patients’ T cell populations can become compromised, with fewer healthy T cells present. This can lead to12-14:

  • Continued immune dysfunction
  • Uncontrolled residual disease

Triple class–exposed* patients are in need of a novel treatment that:

  • Can deliver deep responses with long durations of response5
  • Alleviates the need for repeated administration15,16
  • Increases quality of life6,7

Harnessing the power of the immune system early, while these immune cells are healthy, represents an important window of opportunity12

Information Icon

Although treatment of RRMM is evolving, an unmet need remains—especially for triple class–exposed* patients.1-3

See more data for
triple class–exposed* patients

Find a certified
treatment center near you

CR=complete response; mPFS=median progression-free survival; ORR=overall response rate; PI=proteasome inhibitor; RRMM=relapsed/refractory multiple myeloma.

Received an IMiD® agent, a PI, and an anti-CD38 antibody.